Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 10;615(7953):687–696. doi: 10.1038/s41586-022-05531-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 4 — a) Absolute lymphocyte counts according to the original conditioning chemotherapy regimen (top), or the revised conditioning chemotherapy regimen (bottom). Patients treated with IL-2 combination therapy are indicated by dotted lines. b) Time to generate neoTCR T cell product for 16 dosed patients, ordered by consent date. * 0010: Due to COVID-19 shutdown in 2020 and updates to the manufacturing process, the patient underwent two apheresis and two manufactures of cell therapy products. # 0603: NeoTCR isolation was done three times for repeated attempts to find neoTCRs available for product selection. ^ 0026: Went through five separate PBMC samples before suitable neoTCRs were identified for product selection. ** 1003: Went through two manufactures of the cell therapy product. c) NeoTCR percentage (top) and counts (bottom) by dose level, separated by individual neoTCR (up to 3 per patient). Peripheral blood analysis of neoTCR cells in patients treated with dose level 1 (left), dose level 2 (centre), and dose level 3 (right). Total number of neoTCR cells was calculated per μL of blood per patient. Count information was not available for all timepoints. Patients treated with IL-2 are shown with dotted lines. d) Gene editing efficiency of final cell product correlates with neoTCR+ cells detected post-infusion. Percent of neoTCR+ cells infused in each patient (left; correlation Pearson r = 0.8463, ****P < 0.0001). Percent of neoTCR+ cells infused per TCR (right; correlation Spearman r = 0.7475, ****P < 0.0001). Area under the curve (AUC) was calculated from day 0 (pre-infusion) up to day 7. Data not shown for patient 0404; no day 0–7 post-infusion samples available.